2020
NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Dahal K, Mosleh W, Almnajam M, Khaddr M, Adeel M, Vashist A, Robinson P, Azrin M, Lee J. NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2020, 21: 1202-1208. PMID: 32173329, DOI: 10.1016/j.carrev.2020.03.012.Peer-Reviewed Original ResearchConceptsAcute coronary syndromePercutaneous coronary interventionRandomized clinical trialsDual therapyTriple therapyStent thrombosisAtrial fibrillationCoronary syndromeCoronary interventionSystematic reviewRelevant non-major bleedingRisk of STComposite of mortalityConcomitant atrial fibrillationEfficacy of NOACsMajor efficacy outcomeNon-major bleedingTIMI minor bleedingDual antiplatelet therapyPrimary safety outcomeBleeding outcomesCRNM bleedingIschemic outcomesISTH majorP2Y12 agents
2018
Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma
Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. Journal Of Clinical Medicine 2018, 7: 74. PMID: 29642547, PMCID: PMC5920448, DOI: 10.3390/jcm7040074.Peer-Reviewed Original ResearchAcute coronary syndromePercutaneous coronary interventionDAPT durationDuration of DAPTOlder patient populationCoronary artery diseasePotent antiplatelet agentsMajor societal guidelinesNovel anticoagulant drugsAntiplatelet therapyCoronary syndromeMultiple comorbiditiesP2Y12 inhibitorsTriple therapyCoronary interventionAntiplatelet agentsArtery diseasePatient populationSocietal guidelinesAnticoagulant drugsOptimal durationClinical decisionAvailable evidenceTherapyNew stent